Form4insider filings, from the source

SEC Form 4 · accession 0001104659-18-036483

Kiniksa Pharmaceuticals International, plc · KNSA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Chris Heberlig
Officer — Exec VP & CFO
Period of report
May 29, 2018
Accepted (ET)
May 29, 2018 · 7:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001730430

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Class A Common SharesMay 29, 2018C6,392$0.00A42,991D
Class A Common Sharesholding———36,598IBy Sandra C. Heberlig as trustee for the Christopher J. Heberlig 2017 Irrevocable Trust

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Series C Preferred SharesF2,F1—Feb 9, 2018P6,392A——Class A Common Shares6,3926,392D
Series A Preferred SharesF3—May 29, 2018C74,935D——Class B Common Shares74,9350D
Series C Preferred SharesF1—May 29, 2018C6,392D——Class A Common Shares6,3920D
Class B Common SharesF4—May 29, 2018C74,935A——Class A Common Shares74,935440,920D

Explanation of responses